A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

* Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective. * Subjects with brain metastases must have clinically controlled neurologic symptoms. * Subject is able to swallow and retain oral medications and does not have uncontrolled emesis. * Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.

* Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia. * Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult. * Subject has a history of cardiac conduction abnormalities. * Subject has a significant history of cardiovascular disease. * Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy. * Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose. * Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.